OncoLink en espanõl
Share
Types of Cancer > Sarcomas > Rhabdomyosarcoma and Other Soft-Tissue Sarcomas > News
May 2009
Adjunctive anti-GD2 immunotherapy effective for high-risk neuroblastoma
February 2009
Radiosurgery effective for vestibular schwannomas with neurofibromatosis type 2
January 2009
Prenatal and perinatal distress may increase risk of neuroblastoma
November 2008
Virus-specific T cells modified to attack neuroblastoma cells
August 2008
Familial neuroblastoma linked to ALK mutations
July 2008
CHD5 gene suppression tied to poor outcome in neuroblastomas
May 2008
Genetic variants on chromosome 6 linked to neuroblastoma susceptibility
April 2008
Inhibition of ODC1 gene seen as new approach to treating neuroblastoma
January 2008
Biopsy is usually best first option for locally advanced rhabdomyosarcoma
June 2007
Less aggressive approach to neuroblastoma still effective
April 2007
Attenuated poliovirus eradicates neuroblastomas
August 2006
Bortezomib effective against neuroblastoma in animal studies
Endogenous retrovirus in mouse neuroblastoma involved in tumor growth
July 2006
Ototoxicity from high-dose cisplatin a problem in neuroblastoma therapy
February 2006
Interleukin-12 boosts apoptosis, survival in mouse model of neuroblastoma
January 2006
Immunotherapy may prevent neuroblastoma relapse
Loss of caspase-8 facilitates spread of neuroblastoma
November 2005
Chromosome abnormalities linked to worse outcome in neuroblastoma patients
October 2005
Transcription factor acts as tumor suppressor in rhabdomyosarcoma
August 2005
Hearing loss still common after low-dose radiation for vestibular schwannoma
June 2005
Strontium-89 and chemotherapy curb bone cancer pain
May 2005
Chromosome 11q deletion predicts poor outcome of neuroblastoma
April 2005
EMP3 may be neuroblastoma and glioma suppressor gene
January 2005
Polyomavirus infection in pregnancy not linked with neuroblastoma in child
December 2004
Herpes virus mutant shows potential for neuroblastoma
November 2004
Newly discovered TrkA splice variant a tumor-promotor in neuroblastoma
May 2004
Research confirms good prognosis for pelvic neuroblastoma
Chemokine attracts killer T cells to neuroblastomas
Day care, childhood infection, and allergies linked to reduced neuroblastoma risk
Topotecan after cyclophosphamide active, tolerated in pediatric rhabdomyosarcoma
December 2003
Risk of second cancers increased for decades after neuroblastoma treatment
October 2003
Lower neuroblastoma rates linked to folate fortification
September 2003
Antisense oncogene inhibition suppresses neuroblastoma growth
August 2003
Gleevec inhibits proliferation of aggressive neuroblastomas
July 2003
Surgery alone may be best treatment for local-regional neuroblastoma
May 2003
Proliferation-associated protein tied to neuroblastoma outcome
Synthetic retinoid shows activity against experimental neuroblastoma
April 2003
Folate fortification reduces incidence of neuroblastoma
February 2003
Geldanamycin shows activity against neuroblastoma cells
December 2002
Intensified chemotherapy aids survival in neuroblastoma with MYCN amplification
November 2002
Enkephalin-expressing vector cuts bone cancer pain in mice
August 2002
Maternal vitamin use significantly reduces neuroblastoma risk
Decoy receptor causes vessel regression in neuroblastoma model
May 2002
Elevated CRP may predict progression of malignant fibrous histiocytoma
April 2002
Screening infants for neuroblastoma does not reduce mortality
March 2002
Infant screening programme for neuroblastoma raises controversy in Germany
Ras gene may play role in neuroblastoma cell death
Results excellent for microsurgical excision of nonvestibular brain schwannomas
January 2002
Presence of protein Id2 in neuroblastoma signifies aggressiveness
November 2001
Monoclonal antibody plus GM-CSF holds promise for neuroblastoma
May 2001
Histologic grading of soft-tissue sarcomas does not replace subtyping
August 2000
Early infancy screening program for neuroblastoma may be unnecessary
Telomerase gene expression predicts neuroblastoma clinical outcome
March 2000
St. Jude halts two more neuroblastoma gene therapy trials
October 1999
New treatment protocols improve outcomes of children with high-risk neuroblastoma